Transcode Therapeutics names Interim CFO John A. Tattory in initial beneficial ownership filing

• Transcode Therapeutics Interim CFO John A. Tattory filed an initial Form 3 beneficial ownership statement dated Sept. 10, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transcode Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-109371), on September 21, 2026, and is solely responsible for the information contained therein.